Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 5Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 16Myelodysplastic Syndromes 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Anemia, Refractory, with Excess of Blasts 5Myeloproliferative Disorders 4Lymphoma, Non-Hodgkin 3Leukemia, Myelomonocytic, Chronic 3Hematologic Neoplasms 3Graft vs Host Disease 3Recurrence 2Neuroblastoma 2Neoplasms 2Neoplasm, Residual 2Myelodysplastic-Myeloproliferative Diseases 2Multiple Myeloma 2Lymphoma 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Biphenotypic, Acute 2Leukemia 2Hodgkin Disease 2beta-Thalassemia 1Primary Myelofibrosis 1Neurofibromatosis 1 1Metabolic Diseases 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Extranodal NK-T-Cell 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid 1

Interventions

N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 9Cyclophosphamide 9Prednisone 8Doxorubicin 7Vincristine 6Azacitidine 5pembrolizumab 3fludarabine 3belinostat 3Lenalidomide 3Brentuximab Vedotin 310-propargyl-10-deazaaminopterin 3ruxolitinib 2duvelisib 2Gemcitabine 2Dexamethasone 2Biopsy 2Bendamustine Hydrochloride 2venetoclax 1spartalizumab 1somatostatin, cyclic hexapeptide(Phe-Phe-Trp-Lys-Thr-Phe)- 1sodium-iodide symporter 1sintilimab 1pomalidomide 1ixazomib 1ivarmacitinib 1daratumumab 1cemiplimab 1calaspargase pegol 1X-Rays 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Lymphoma, T-Cell, Peripheral × Busulfan × Clear all
NCT06468267 2024-08-01

RIC With Thiotepa Combined With Bu/Flu/Ara-C in Allo-HSCT for Relapsed or Refractory PTCL.

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Phase 2 Recruiting
50 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡